Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
19 participants
INTERVENTIONAL
2008-12-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Open-label Study to Evaluate Topiramate Therapy in Migraine Patients, and Its Effects on Subject Responsiveness to Migraine Treatment With Triptans
NCT00261469
Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine
NCT03280342
A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine
NCT00236509
A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine
NCT00231595
A Study of the Effectiveness and Safety of Topiramate for the Prevention of Migraine
NCT00253175
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Topiramate
topiramate 25mg twice for 1 week -\> topiramate 50mg twice for 7 weeks
Topiramate
topiramate 25mg twice 1 week -\> topiramate 50mg twice 7 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Topiramate
topiramate 25mg twice 1 week -\> topiramate 50mg twice 7 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* newly-diagnosed patients with migraine without aura (International Headache Society classification)
* symptom frequency (at least 2 episodes of migraine attack/month)
Exclusion Criteria
* patients with cardiovascular risk factors (hypertension, diabetes, hyperlipidemia, smoking)
* patients who take antihypertensive agent or antidepressant
* patients who were pregnant, breast-feeding or actively smoking
* patients with neurological or cerebrovascular diseases
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SMG-SNU Boramae Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hyunwoo Nam
SMG-SNU Boramae Medical Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hyunwoo Nam, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
SMG-SNU Boramae Medical Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
06-2008-71
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.